Genentech in rare deal to buy preclinical tumour metabolism programme from Forma
This article was originally published in Scrip
Executive Summary
Genentech has agreed to a deal whereby it gains exclusive worldwide rights to a preclinical small-molecule anticancer programme from the three-year-old US drug discovery firm Forma Therapeutics.